Zimbabwe has turned down a significant American health deal worth $367m (272 million pounds) spanning five years over Washington's insistence on sensitive data.
This rejection came to light following a internal memorandum from December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official representative later explained that the United States was seeking health data for research and profit while was not willing to share the resulting advantages from any future vaccines.
"We are forced to start the challenging and unfortunate process of scaling back our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged more dialogue to find a deal acceptable to all parties so the nation's vital HIV treatment initiative can proceed.
Wider Background
This rejection comes after a similar situation in neighbouring Kenya, where a high court blocked a related health funding agreement following concerns were raised about the security of Kenyans' health data.
Since resuming office last year, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump claimed its expenditure was "wasteful" and his government was seeking government-to-government deals to enhance openness and accountability.
Based on reports, Sixteen African countries have so far agreed to these new health pacts, constituting more than $18.3bn of fresh investment.
Details of the Rejected Agreement
The funds for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million presently on antiretroviral therapy via US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to share its biological resources and data for a long time, with no equivalent guarantee of access to any scientific breakthroughs – like new medicines or tests – that might result from that provided information," he stated.
"In essence, our nation would provide the basic resources for medical research without any certainty that the end products would be accessible to our people should a future pandemic arise."
National Interest and International Frameworks
He also said that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were undermining structures previously set up via the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system designed to manage future pandemics.
"This framework is designed to guarantee that when a country provides its data, the benefits – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as opposition to America," he added.
"We encourage further dialogue with our US partners on how future collaboration could be structured in a manner that honours the independence and interests of each country."
Medical Community Response
Medical experts said it understood the official position, but urged that negotiations should continue considering much of the country's HIV programmes were funded by foreign aid.
"In cases where technical issues exist, such as those involving information security or agreement terms, these can frequently be addressed via technical clarification and mutually agreed protections," it said.
This impasse highlights the complex challenges between receiving much-needed foreign assistance and safeguarding local interests in an increasingly data-driven world.